Grade My Investments
HomeFree Stock Grades › TVTX

Travere Therapeutics, Inc. (TVTX) Stock Grade

TVTX · Healthcare

A+
Grade updated: July 18, 2026
Computed by the GradeMyInvestments scoring model from revenue growth, profitability, balance-sheet strength, and analyst targets.
Market Cap
$3.4B
P/E Ratio
Revenue Growth (YoY)
+110.5%
Net Margin
-5.2%
Return on Equity
Dividend Yield
None

About Travere Therapeutics, Inc.'s fundamentals

Travere Therapeutics is a biotechnology company with a market capitalization of $3.4 billion that demonstrated strong revenue growth of 110.5% year-over-year, indicating significant expansion in its commercial operations. However, the company reported a net loss in its latest annual statement with a net margin of -5.2%, meaning it is not yet profitable despite its revenue gains. The company does not currently pay a dividend, which is typical for biotech firms in growth or investment phases.

Track TVTX free — no credit card required. Live grade + monthly AI report →